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A 48-year-old man, using statin, was admitted to hospital with progressive myalgia after consumption of tadalaﬁl and simvastatin.
Muscle pain and penile erection disappeared seven days after interruption of therapy. This case demonstrates the interaction of
tadalaﬁl with simvastatin resulting in myopathy. Muscle damage could be attributed to the common metabolic way of these two
drugs which is cytochrome P450 isoenzyme system.
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1.Background
Cardiovascular disease and erectile dysfunction (ED) share
similar etiologic and pathophysiologic pathway. Mainly it is
wellknownthatmostcasesofEDderivefromanimpairment
of the vascular endothelium. Recent epidemiological studies
have underlined the close association between ED and
comorbidconditionssuchashypertension,diabetesmellitus,
and dyslipidemia. Actually phosphodiesterase type 5 (PDE5)
inhibitors are recommended as ﬁrst-line therapy for erection
problems of all etiologies and severities, at the same time
statins are a recommended therapy for vascular disorders
[1]. Pharmacologic data support a potential interactions
between these drugs because PDE5 inhibitors and statins
are metabolized by the liver via the cytochrome P450. In
this family of enzymes, CYP3A is the dominant CYP in
terms of both expression levels in the liver and the number
of drugs metabolized [2]. Both simvastatin and tadalaﬁl
metabolism involve principally CYP3A. The metabolism of
simvastatininhumanlivermicrosomesiscatalysedprimarily
(≥80%) by CYP3A4/5, with a minor contribution (≤20%)
from CYP2C8. Tadalaﬁl during its metabolism is converted
to a metabolite that binds irreversibly to the enzyme active
site, permanently inactivating the enzyme. The inactivated
enzymemustbereplacedbynewlysynthesizedCYPtoregain
activity [3]. Today in addition to the classical proerectile-
eﬀect, several studies have demonstrated that PDE5 can also
inﬂuence vascular endothelium; given that the combinated
therapystatinsplusPDE5couldbeveryusefulinpatientwith
high cardiovascular risk [4, 5].
2.CaseReport
A 48-year-old man with a history of dyslipidemia and
erectile dysfunction was admitted to our department due to
a manifestation of progressive myalgia after comsumption
of tadalaﬁl. He had been taking simvastatin at doses of
20mg/die for almost 8 days and recently he was prescribed
tadalaﬁl. Approximately 3 hours after the patient began
tadalaﬁl, he developed unexplained, severe muscle aches
(particularly in the lower extremities). Gradually, these
symptoms worsened with severe pain in the 3/5 of surface
area over upper extremities and 2/5 of surface area over
lower extremities, weakness in the pelvic and shoulder girdle
regions. The penile erection was maintained for ﬁve days.
According to his clinical history we stopped tadalaﬁl and
simvastatin therapy and we noted a signiﬁcant improvement
in muscular symptoms after 5 days. Further questioning
revealed no symptoms of viral illness, or other identiﬁable
causes of myalgias. He denied unusual or abnormal physical
activity, trauma, burns, recent intramuscular injections or
symptoms of coronary artery disease. His temperature
was 37◦C, pulse rate 87b/min and blood pressure 125/75
mmHg. Laboratoristic analysis are reported in the Table 1.
No substantial changes in the ECG were noted. Myopathy,
probably drug induced, was diagnosed because there was no2 Case Reports in Medicine
Table 1: Serum values of some parameters during 5 days.
Normal range
AST (14–41U/L) 65 74 60 51 39
ALT (9–63U/L) 76 82 71 64 55
γ G T ( 7 – 5 0 U / L ) 7 19 68 07 07 2
CK (38–190U/L) 326 444 384 210 187
Myoglobin (0–116μg/L) 247 289 204 145 125
Urea (3–8mmol/L) 16 14 10 8 8
Creatinine (0.06–0.12mmol/L) 0.15 0.12 0.08 0.06 0.07
Total bilirubin (<20μmol/L) 15 14 16 14 12
evidenceofrecenttraumaorotherpotentialcausesofmuscle
damage. An intravenous ﬂuid supplement was prescribed,
but the weakness decreased slightly after he was discharged.
3. Discussion
Approximately 95% of statin-treated patients tolerate this
treatment without any adverse eﬀects. Tadalaﬁl (Cialis) is
a potent reversible phosphodiesterase-5 inhibitor used for
the treatment of erectile dysfunction. Physiologically, in
response to sexual stimulation, nitric oxide is released into
the smooth muscle of the corpus cavernosum of the penis,
resulting in elevation of cGMP levels and relaxation of
the smooth muscle to produce an erection [6, 7]. Patients
who are treated for erectile dysfunction are likely to take
additional medications for preexisting conditions such as
cardiovascular disease [8]. Statins and tadalaﬁl are both
metabolized by the cytochrome P450 isoenzyme system
(particularly CYP3A4). In this family of enzymes, CYP3A
is the dominant CYP in terms of both expression levels
in the liver and the number of drugs metabolized. As a
result of the broad substrate speciﬁcity exhibited by CYP3A
and the polypharmacy often used by patients, alterations
in CYP3A activity by induction or inhibition can result in
metabolically based drug-drug interactions. In vitro studies
were performed examining the ability of tadalaﬁl to alter
metabolism mediated by CYP3A in cultures of human
hepatocytes or reversibly inhibit metabolism mediated by
CYP3A in human liver microsomes. In addition, tadalaﬁl
was examined for its ability to cause mechanism-based
inhibition of CYP3A-mediated reactions in human liver
microsomes. Mechanism-based inhibition occurs when the
drug is converted to a metabolite that binds irreversibly to
the enzyme active site, permanently inactivating the enzyme.
The inactivated enzyme must be replaced by newly synthe-
sized CYP to regain activity; thus recovery is slowed after
mechanism-based inactivation as compared with reversible
inhibition [2, 3]. Other in vitro studies evaluated the eﬀect
of tadalaﬁl on the pharmacokinetics of coadministered drugs
that are metabolized by CYP3A such as lovastatin. This study
remarks that side eﬀects such as myopathy could be even
higher if a statin is used concomitantly with one of the
most potent CYP3A4 inhibitors such as tadalaﬁl. So their
concomitant use should be avoided. Though the meaning of
this case is yet not clear, we speculate that this fatigue may
b ed u et oal o w - g r a d em u s c l ed a m a g ei n d u c e db yt a d a l a ﬁ l .
Muscle toxicity is a potential adverse eﬀect not only for
statins, but also with 5PD . So a combination of tadalaﬁl and
statins may enhance the eﬀect and induce muscle toxicity
[9, 10]. In the patients treated with statins, tadalaﬁl should
not be the PDE5 inhibitors of ﬁrst choice, because of its long
half-life in order to avoid potentially life-threatening adverse
eﬀects.
4. Conclusion
Statins are used to reduce blood cholesterol and have been
shown in multiple studies to reduce the risk of heart attacks,
heart attack deaths, and strokes. The beneﬁts of treating
blood cholesterol with statins have been demonstrated in a
wide variety of patient groups, including healthy patients.
The major medical problem with statins is that they can
produce muscle aching, weakness, and cramps in some
patients. The incidence of myopathy could be even higher if
simvastatin is used concomitantly with CYP3A4 inhibitors
such as 5PDi. Moreover muscle toxicity is a potential adverse
eﬀect not only for statins, but also with 5PDi so their
concomitant use should be carefully monitored. Specially
in the patients treated with statins, tadalaﬁl should not be
the PDE5 inhibitors of ﬁrst choice, because of its long half-
life [11]. At the same time the best statin to use might
be rosuvastatin because it is not extensively metabolized by
isoenzymes of the CYP system [12].
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